infant appeared healthy at birth | Age | Informed Consent parent | Duration of gestation | Hepatitis B Vaccine Dose Birth time
Item
• healthy infants 56-83 days of age at the time of the first vaccine dose, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks & has received a birth dose of hepatitis b vaccine within the first 3 days of life.
boolean
C2049683 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0021430 (UMLS CUI [3,1])
C0030551 (UMLS CUI [3,2])
C0460089 (UMLS CUI [4])
C2240392 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C2736116 (UMLS CUI [5,3])
Immunologic Deficiency Syndromes | Medical History | Physical Examination
Item
any confirmed immunodeficient condition, based on medical history and physical examination.
boolean
C0021051 (UMLS CUI [1])
C0262926 (UMLS CUI [2])
C0031809 (UMLS CUI [3])
Vaccine Planned | Oral Poliovirus Vaccine
Item
planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period with the exception of oral polio vaccine (opv).
boolean
C0042210 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C0032375 (UMLS CUI [2])
Investigational New Drugs | Drugs, Non-Prescription | Vaccine Investigational
Item
use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
boolean
C0013230 (UMLS CUI [1])
C0013231 (UMLS CUI [2])
C0042210 (UMLS CUI [3,1])
C1517586 (UMLS CUI [3,2])
Immunosuppressive Agents chronic | Biological Response Modifiers chronic
Item
chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
BCG Vaccine
Item
bacille calmette-guérin (bcg) vaccine received after the first 2 weeks of life.
boolean
C0004886 (UMLS CUI [1])
Vaccination Against Diphtheria | Vaccination Against Tetanus | Vaccination Against Pertussis | Vaccination Against Haemophilus influenzae type b | Vaccination Against Meningococcal Infections
Item
previous vaccination against diphtheria, tetanus, pertussis, haemophilus influenzae type b, and/or meningococcal disease.
boolean
C0042196 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0012546 (UMLS CUI [1,3])
C0042196 (UMLS CUI [2,1])
C0521124 (UMLS CUI [2,2])
C0039614 (UMLS CUI [2,3])
C0042196 (UMLS CUI [3,1])
C0521124 (UMLS CUI [3,2])
C0043167 (UMLS CUI [3,3])
C0042196 (UMLS CUI [4,1])
C0521124 (UMLS CUI [4,2])
C0121772 (UMLS CUI [4,3])
C0042196 (UMLS CUI [5,1])
C0521124 (UMLS CUI [5,2])
C0025303 (UMLS CUI [5,3])
Exposure to Diphtheria | Exposure to Tetanus | Exposure to Pertussis | Exposure to Hepatitis B | Exposure to Haemophilus influenzae type b | Exposure to Meningococcal Infections
Item
history of diphtheria, tetanus, pertussis, hepatitis b, haemophilus influenzae type b and/or meningococcal disease or known exposure to these diseases since birth.
boolean
C0332157 (UMLS CUI [1,1])
C0012546 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0039614 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C0043167 (UMLS CUI [3,2])
C0332157 (UMLS CUI [4,1])
C0019163 (UMLS CUI [4,2])
C0332157 (UMLS CUI [5,1])
C0121772 (UMLS CUI [5,2])
C0332157 (UMLS CUI [6,1])
C0025303 (UMLS CUI [6,2])
Immunoglobulins | Blood product
Item
administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
boolean
C0021027 (UMLS CUI [1])
C0456388 (UMLS CUI [2])